Obesity & Metabolism
Voiant advances obesity clinical trial imaging beyond BMI with deeper metabolic and body composition insight.
As obesity therapeutics evolve toward optimization of body composition and metabolic health, sponsors increasingly seek to understand treatment effects that cannot be fully captured by body weight or BMI alone, including changes in fat distribution, muscle health, and lean mass preservation.
Built for the next generation of obesity clinical trials, Voiant combines deep scientific expertise, hands-on operational support, and advanced technology to support body composition and metabolic imaging endpoints. Our integrated approach leverages multimodal imaging, including MRI and DXA, alongside centralized quality control, endpoint management, and regulatory-ready data delivery. Through Voiant Hub®, sponsors gain a seamless imaging workflow that streamlines study execution and delivers high-quality imaging insights for faster, more confident clinical decisions.
OBESITY Imaging Expertise
Meaningful obesity endpoints require more than image collection alone. Today’s obesity trials are increasingly focused on understanding the composition of weight loss, including changes in fat mass, lean mass, skeletal muscle, fat distribution, and metabolic health. Voiant combines multimodality imaging, endpoint expertise, and centralized operational oversight to help sponsors characterize clinically meaningful outcomes beyond weight loss, while delivering consistent, regulatory-ready data across every stage of a clinical trial.
Specialized Operational Execution
Voiant delivers the global operational rigor required to generate consistent, high-quality imaging endpoints in obesity clinical trials. Central to this is our hands-on approach to site and technologist support: in-house DXA SMEs engage directly with sites during implementation and throughout the trial, providing real-time feedback to prevent image quality issues before they affect study timelines. Through standardized workflows, centralized quality management, and global execution capabilities, we help sponsors reduce variability and maintain confidence in their imaging data.
- Hands-on site and technologist support during implementation and throughout the trial, with direct engagement to proactively manage image quality
- Centralized quality control and image review
- Cross-site and cross-vendor harmonization
- Endpoint management and data consistency oversight
- Inspection-ready workflows and audit trails
- Regulatory-ready reporting and data delivery
Our infrastructure ensures reproducible, regulatory-ready data, even in complex, multi-site obesity trials.
Complementary Modality Services
Voiant supports obesity clinical trials with a complementary multimodality imaging approach designed to evaluate body composition and metabolic effects across study timepoints. Our strategy helps sponsors generate deeper insight into the quality of weight loss, including the preservation of lean mass and muscle health, to better characterize therapeutic impact.
MRI (Magnetic Resonance Imaging)
- Visceral and Subcutaneous Adipose Tissue Quantification
- Skeletal Muscle Volume and Composition
- Muscle Fat Infiltration Assessment
- Liver Fat Quantification (Proton Density Fat Fraction, PDFF)
- Magnetic Resonance Elastography (MRE)
- Pancreatic Fat Assessment
- Organ-Specific Metabolic Characterization
DXA (Dual-energy X-ray Absorptiometry)
- Fat Mass vs. Lean Mass Distribution
- Bone Mineral Density
- Appendicular Lean Mass Assessment
- Body Composition Assessment
- Regional Body Composition Analysis
- Longitudinal Body Composition Monitoring
CT (Computed Tomography)
- Opportunistic Body Composition Assessment
- Anatomical Characterization
- Exploratory Imaging Endpoints (when clinically appropriate)
Expanding Biomarker Capabilities
Powered by Voiant Hub 2.0, our endpoint and analytics capabilities help sponsors better understand the composition of weight loss, not simply the magnitude of weight loss. These imaging biomarkers characterize changes across body composition, lean mass preservation, muscle health, and organ-level metabolism to help evaluate and differentiate obesity therapies.
Body Composition
- Fat Mass vs. Lean Mass
- Bone Mineral Density
- Visceral Adipose Tissue (VAT) vs. Subcutaneous Adipose Tissue (SAT)
- Regional Adipose Tissue Distribution
- Appendicular Lean Mass
- Percentage Lean Mass Change
Muscle Health
- Muscle Volume and Quality
- Fat Infiltration
- Sarcopenia Risk Assessment
- Myosteatosis Characterization
- Muscle Composition and Quality Measures
Organ-Level Metabolism
- Liver Fat Quantification (Proton Density Fat Fraction, PDFF)
- Pancreatic Fat Quantification
- Ectopic Fat Deposition Across Metabolic Tissues
- Hepatic Steatosis Assessment
Your imaging partner from start to endpoint
Learn more about how Voiant’s innovative solutions and expert services can provide custom-tailored support for your next trial.